Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma Plasma cell neoplasm	NCT ID:	NCT07555938
Trial Phases:	Phase III	Protocol IDs:	CO46096 (primary) NCI-2026-03962 2025-524028-23-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT07555938

Summary

The purpose of this study is to assess the efficacy and safety of cevostamab in
combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC)
in participants with multiple myeloma (MM) who have received one to three prior lines of
therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.